PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Jakob, T.* ; Rauber, M.M.* ; Perez-Riverol, A.* ; Spillner, E.* ; Blank, S.

The honeybee venom major allergen api m 10 (Icarapin) and its role in diagnostics and treatment of hymenoptera venom allergy.

Curr. Allergy Asthma Rep. 20:48 (2020)
Verlagsversion DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
Purpose of Review In Hymenoptera venom allergy, the research focus has moved from whole venoms to individual allergenic molecules. Api m 10 (icarapin) has been described as a major allergen of honeybee venom (HBV) with potentially high relevance for diagnostics and therapy of venom allergy. Here, we review recent studies on Api m 10 characteristics as well as its role in component-resolved diagnostics and potential implications for venom-specific immunotherapy (VIT). Recent Findings Api m 10 is a major allergen of low abundance in HBV. It is an obviously unstable protein of unknown function that exhibits homologs in other insect species. Despite its low abundance in HBV, 35 to 72% of HBV-allergic patients show relevant sensitization to this allergen. Api m 10 is a marker allergen for HBV sensitization, which in many cases can help to identify primary sensitization to HBV and, hence, to discriminate between genuine sensitization and cross-reactivity. Moreover, Api m 10 might support personalized risk stratification in VIT, as dominant sensitization to Api m 10 has been identified as risk factor for treatment failure. This might be of particular importance since Api m 10 is strongly underrepresented in some therapeutic preparations commonly used for VIT. Although the role of Api m 10 in HBV allergy and tolerance induction during VIT is not fully understood, it certainly is a useful tool to unravel primary sensitization and individual sensitization profiles in component-resolved diagnostics (CRD). Moreover, a potential of Api m 10 to contribute to personalized treatment strategies in HBV allergy is emerging.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
3.577
1.139
3
4
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter Allergen-specific Immunotherapy ; Api M 10 ; Component-resolved Allergy Diagnostics ; Honeybee Venom Allergy ; Icarapin ; Venom Immunotherapy; Rves V 5; Ige; Bee; Protein; Immunotherapy; Sensitization; Sensitivity; Products; Isoforms
Sprache englisch
Veröffentlichungsjahr 2020
HGF-Berichtsjahr 2020
ISSN (print) / ISBN 1529-7322
e-ISSN 1534-6315
Zeitschrift Current Allergy and Asthma Reports
Quellenangaben Band: 20, Heft: 9, Seiten: , Artikelnummer: 48 Supplement: ,
Verlag Current Science Inc.
Verlagsort 400 Market Street, Ste 700, Philadelphia, Pa 19106 Usa
Begutachtungsstatus Peer reviewed
Institut(e) Institute for Allergy Research (IAF)
POF Topic(s) 30202 - Environmental Health
Forschungsfeld(er) Allergy
PSP-Element(e) G-505400-001
DOI 10.1007/s11882-020-00943-3
WOS ID WOS:000542718700002
Scopus ID 85086511661
PubMed ID 32548726
Erfassungsdatum 2020-06-29
[➜Korrektur melden]